Ayala Pharmaceuticals Inc (ADXS): SGEN/GEN.CO PR on phase-2 trial in cervi...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	830
Posts	119741
Boards Moderated	17
Alias Born	09/05/2002

DewDiligence

Re: None

Tuesday, 10/10/2017 1:43:05 PM

Tuesday, October 10, 2017 1:43:05 PM

SGEN/GEN.CO PR on phase-2 trial in cervical cancer has excerpt relevant to ADXS:

https://www.businesswire.com/news/home/20171010005937/en

“We are very pleased to see the clinical development of tisotumab vedotin progress in patients with cervical cancer—an area with a strong unmet medical need. The study provides an opportunity for accelerated registration.”

…“Based on promising data from the phase 1/2 clinical trial of tisotumab vedotin in recurrent and/or metastatic cervical cancer and feedback from the Food and Drug Administration (FDA) on the planned trial, we and Genmab are advancing the program into a potentially registrational study for these patients with high unmet medical need.”

The study in question will be single-arm and have about 100 patients. The primary endpoint is ORR.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”